Why Elevidys Matters for Sarepta Therapeutics Inc (SRPT) Stock

SRPT shares have fallen 11.4% in the last 24 hours, with the RSI entering oversold territory at 22.8. The MACD remains below the signal line and in negative territory, while the price is trading below both the 20-day and 50-day moving averages. Although the headline emphasizes the significance of Elevidys, current technical indicators suggest that selling pressure may persist in the short term. The oversold condition could trigger a short-term bounce, but given the downward trend, a continued decline is more likely.